Cytokines News and Research

Latest Cytokines News and Research

Ethanol, nonalcoholic compounds in red wine may reduce risk of vascular disease

Observational epidemiologic studies relating wine and alcohol to health all suffer from the fact that they, of necessity, compare people who prefer certain beverages, but not the beverages themselves. While there have been many intervention trials in animals, randomized trials in humans are less common. Randomized crossover trials, in which each subject receives all interventions in sequence, can be especially important as they tend to avoid baseline differences among subjects and can detect effects of different interventions with smaller numbers of subjects.

18 Jan 2012

Intestinal worm infections may not be bad

Intestinal worm infections may not be all bad, according to a new study by William C. Gause, PhD, and colleagues at UMDNJ- New Jersey Medical School. The researchers have found cytokines that help oust intestinal worm infections in mice also soothe associated lung injury and inflammation.

11 Jan 2012

Statin use may influence susceptibility to ILD in smokers

Use of statins may influence susceptibility to or the progression of interstitial lung disease (ILD) in smokers, according to a new study.

6 Jan 2012

Pfizer, Karo Bio partner to develop RORgamma modulators for autoimmune diseases

Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.

26 Dec 2011

H2S plays critical role in signaling pathway linked to Alzheimer's and Parkinson's

Something rotten never smelled so sweet. This is what members of a team of scientists at Cold Spring Harbor Laboratory (CSHL) are telling one another as they discuss a new finding they did not expect to make. They have discovered that hydrogen sulfide (H2S) - the flammable, highly toxic gas that we usually associate with the smell of rotten eggs in landfills and sewers - plays an important role in the regulation of a signaling pathway implicated in biological malfunctions linked to Alzheimer's and Parkinson's diseases, among others.

14 Dec 2011

Syndax announces data from entinostat phase 2 study on HL

Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.

12 Dec 2011

Positive dose-escalation/expansion data from Array BioPharma's ARRY-614 Phase 1 MDS study

Array BioPharma Inc. today announced positive dose-escalation/expansion data for its novel, small molecule dual p38/Tie2 inhibitor, ARRY-614.

12 Dec 2011

Idera receives FDA notification to proceed with IMO-3100 Phase 2 clinical trial for psoriasis

Idera Pharmaceuticals, Inc. today announced the receipt of verbal notification from the Food and Drug Administration that the company may proceed with a Phase 2 clinical trial of IMO-3100 in patients with psoriasis based on a trial protocol submitted by the company in October 2011.

2 Dec 2011

Affymetrix signs definitive agreement to acquire eBioscience

Affymetrix, Inc., today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.

30 Nov 2011

TNF inhibitors may minimally increase risk of serious infections

Biologic drugs have revolutionized treatment of autoimmune diseases during the past decade despite belief there is an increased risk for serious infections from using them. But new research from the University of Alabama at Birmingham Center for Education and Research on Therapeutics reveals that a class of biologics called tumor necrosis factor antagonists, or TNF inhibitors, may only minimally increase risk compared to more traditional therapies.

17 Nov 2011

Severity of smoke-inhalation injury may play a role in overall pulmonary inflammatory response

A study of burn patients has found that those who suffered the most severe smoke inhalation also had more inflammation and spent more time on ventilators and in intensive care.

17 Nov 2011

New paper shows how platelets help promote cancer metastasis

About 90 percent of cancer deaths are caused by secondary tumors, known as metastases, which spread from the original tumor site. To become mobile and break free from the original tumor, cancer cells need help from other cells in their environment. Many cells have been implicated in this process, including immune system cells and cells that form connective tissue. Another collaborator in metastasis is platelets, the blood cells whose normal function is to promote blood clotting.

16 Nov 2011

Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012

Concert Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial of CTP-499, a novel agent for the potential treatment of diabetic nephropathy.

14 Nov 2011

UCLA School of Nursing faculty members to present at AHA 2011

A failing heart's effect on the short-term memory. The impact of telephone interventions on behaviors in Latinos. Depression and heart disease. Risk factors contributing to premature coronary atherosclerosis in premenopausal women. These are just a few of the research findings that will be presented by faculty members of the UCLA School of Nursing at the American Heart Association's Scientific Sessions, being held November 12 - 16 in Orlando, FL.

14 Nov 2011